Tirzepatide's 20.9% weight loss superiority over semaglutide and a $550–750/month commercial WAC drive an access squeeze as Medicare Part D coverage remains blocked.
Approximately 100 million US adults meet the diagnostic threshold for obesity (BMI ≥30); approximately 22 million have severe obesity (BMI ≥40). Two GLP-1-based injectable agents dominate the treatment landscape: semaglutide 2.4mg (Wegovy, Novo Nordisk, approved June 2021) and tirzepatide (Zepbound, Eli Lilly, approved November 2023). Tirzepatide's SURMOUNT-1 trial demonstrated 20.9% weight loss vs semaglutide's STEP 1 result of 15.3%, establishing a clear head-to-head efficacy advantage.
Medicare Part D has historically excluded anti-obesity medications, leaving approximately 50 million Medicare beneficiaries without prescription coverage. A proposed 2025 CMS rule to allow GLP-1 agents under Part D remains pending congressional action. Commercial payers require BMI ≥30 with at least one comorbidity (hypertension, Type 2 Diabetes, dyslipidaemia) or BMI ≥35 alone before granting prior authorisation, creating substantial access barriers. Supply constraints for Wegovy persisted through 2023 and have partially eased by Q2 2024.
Approved chronic weight management agents — United States, 2024
| Drug (Brand / INN) | Class | Company | US Approval | Key Trial Result | Commercial PA Routing |
|---|---|---|---|---|---|
| Wegovy (semaglutide 2.4mg) | GLP-1 RA SC | Novo Nordisk | Jun 2021 | STEP 1: 15.3% weight loss vs 2.4% placebo; SELECT: 20% MACE reduction | BMI ≥30 + comorbidity or ≥35; prior auth required; most commercial payers; no Medicare Part D |
| Zepbound (tirzepatide) | GIP/GLP-1 RA SC | Eli Lilly | Nov 2023 | SURMOUNT-1: 20.9% weight loss at 15mg vs 2.4% placebo | BMI ≥30 + comorbidity or ≥35; prior auth required; formulary position still forming; no Medicare Part D |
| Saxenda (liraglutide 3mg) | GLP-1 RA SC | Novo Nordisk | Dec 2014 | SCALE: 8.0% weight loss vs 2.6% placebo | Prior agent in class; declining share vs GLP-1 class successors |
| Qsymia (phentermine/topiramate) | Sympathomimetic + anticonvulsant oral | Vivus | Jul 2012 | EQUIP: 14.7% weight loss at high dose vs 2.5% placebo | Lower cost; fewer PA barriers; preferred at some Medicaid plans |
Sources: FDA Drugs@FDA (approval dates); NEJM STEP 1 (PMID 33567185); NEJM SURMOUNT-1 (PMID 35658024); NEJM SELECT (PMID 37952131); NEJM SCALE (PMID 26132939); CMS 2024 proposed Part D rule.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Current PA language for Zepbound (tirzepatide) and Wegovy (semaglutide) at major commercial payers • BMI threshold and comorbidity requirements by payer and plan type • Preferred drug tier placement and step-edit requirements between agents • Coverage rate benchmarks: commercial vs Medicaid vs Medicare gaps
Delivers
- • CMS proposed rule scope: eligible drugs, BMI criteria, implementation timeline • Market size impact: estimated Medicare-eligible obese population and Part D spend projection • Congressional pathway and opposition analysis • Novo Nordisk and Eli Lilly formulary positioning scenarios under Part D coverage
Delivers
- • Phase 3 readout timelines and PDUFA dates for orforglipron (Lilly oral) and danuglipron (Pfizer oral GLP-1) • Efficacy comparison vs injectable semaglutide: STEP and SURMOUNT benchmarks • Commercial scenario: oral vs injectable formulary preference at commercial payers • Impact on supply constraint narrative if oral agents reach market at scale
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why 100 million US adults meet the BMI 30-plus threshold, with 22 million qualifying as severely obese at BMI 40-plus.
- How two GLP-1 injectables, Wegovy and Zepbound, came to dominate treatment for this population since 2021.
- Why Zepbound's SURMOUNT-1 result of 20.9% weight loss surpasses Wegovy's STEP 1 result of 15.3% at comparable doses.
- How Wegovy's SELECT trial, showing 20% MACE reduction, adds a cardiovascular claim that Zepbound has not yet secured.
- Why Saxenda's 8.0% weight loss result from the SCALE trial lags far behind the GLP-1 successors that followed it.
- How Qsymia's oral 14.7% weight loss result from EQUIP compares on cost and access barriers to injectable GLP-1 agents.
- Why commercial payers require BMI 30 plus a comorbidity, or BMI 35 alone, before granting prior authorization for either agent.
- How Wegovy's supply constraints, which persisted through 2023, had only partially eased by the second quarter of 2024.
- Why roughly 50 million Medicare beneficiaries currently have no Part D prescription coverage for anti-obesity medications at all.
- How the proposed 2025 CMS rule to allow GLP-1 coverage under Part D still awaits congressional action to take effect.
- Why Eli Lilly's oral orforglipron and Pfizer's oral danuglipron could disrupt the injectable GLP-1 market if approved.
- How an oral GLP-1 agent reaching market at scale could reshape the supply-constraint narrative that has defined Wegovy.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US Obesity Competitive Intelligence sources: FDA Drugs@FDA (approval dates and labels), primary trial publications (NEJM: STEP 1, SURMOUNT-1, SELECT, SCALE), ClinicalTrials.gov, major commercial payer PA policy documents (UHC, CVS/Aetna, Cigna), and CMS Part D proposed rule 2025.
- Drug approval dates and label indications verified against FDA Drugs@FDA database
- Clinical trial weight loss results verified against primary NEJM publications (STEP 1, SURMOUNT-1, SCALE)
- SELECT cardiovascular outcome data verified against primary NEJM publication (PMID 37952131)
- Commercial PA criteria verified against current UHC, CVS/Aetna, and Cigna coverage policy documents; Medicare Part D exclusion verified against CMS formulary guidance
Frequently asked questions
Commission this brief
AXLRx delivers US Obesity competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.